FDA Reviews Asthma Drug Omalizumab for Food Allergy Treatment in Children

If approved, the drug could reduce allergic reactions to multiple foods following accidental exposure, with a decision expected in early 2024.

Omalizumab, an existing asthma treatment, shows promise in reducing food allergies in children and is under review by the FDA for this use.
The treatment allows children to consume higher doses of allergenic foods like peanuts, eggs, milk, and cashew without triggering allergic reactions.
If approved, Omalizumab would be the first medicine to reduce allergic reactions to multiple foods following accidental exposure.
Despite the treatment, patients would still need to avoid foods they are allergic to as it is not designed to allow them to freely eat all foods.
The FDA is expected to make a decision on approval in the first quarter of 2024.